Get started
NanoViricides, Inc.NanoViricides, Inc.NanoViricides, Inc.

NanoViricides, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

NNVC trade ideas

$NNVC is gonna fall todayPupm&Dump trading strategy idea. $NNVC is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,17; stop-loss — $5,44; take-profit — $4,62/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:NNVCShort
by KozakHlib
$NNVC is gonna fall todayPupm&Dump trading strategy idea. $NNVC is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,18; stop-loss — $5,41; take-profit — $4,72/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:NNVCShort
by KozakHlib
NNVC -- You Knew That Was Going to Spike AgainThat shaded box, starting from January.19th, was most likely somebody accumulating.. But it looks like the usual suspects, that being: Sabby Management Altrium Capital Empery Asset Management CVI Investments all somehow managed to miss out on this one at the exact same time, because according to the their end of year 13-G reports, they all reported 0% ownership in the company... At times, it seems like the line between hedge fund and underwriter has become blurred with these companies, where it almost looks like they are cooperating with the underwriter during the equity offering process -- but who knows.. Something about this was mentioned in an sec litigation a few years back. “The SEC alleges that a former day trader living in California, Steven Fishoff, schemed with two friends and his brother-in-law to pose as legitimate portfolio managers and induce investment bankers to bring them “over the wall” and share confidential information about an upcoming secondary offering. After promising they wouldn’t disclose the nonpublic information to others or trade an issuer’s stock before an offering was announced, they violated the agreements and tipped each other about the upcoming offerings expected to inherently depress the price of the issuer’s stock. The tippees then shorted the stock before an offering was publicly announced and assured themselves profits on the short sales after the stock price dropped”.
AMEX:NNVC
by stocktradez6
1
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform. $NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2. Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below. NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates. The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses. finance.yahoo.com
AMEX:NNVC
by AlenCiken
2
NNVC - bearish short term (3 days), bullish long term (30 day)after a pattern analysis; NNVC short-term has: a 75% chance of falling to 9.20$ by March 11 at 9:30am open a 25% chance of rising to 12.60$ by march 9 at 1pm and then falling to a price of 11.35$ by open on March 11 at 9:30am chances of rising short term are actually inflated by a few percentage points because of the virus NNVC long-term has: 67% chance of rising after March 11 AT 9:30am until march 17 at 9:30am. PT 16.50$ by March 17 at 9:30am 33% chance of falling after March 11 at 9:30am until March 17 at 9:30am. PT 10.85$ by March 17 at 9:30am Chances of falling are actually inflated long term because of a down trend volume NNVC
AMEX:NNVC
by BenKok
NanoViricide Upside Targets $nnvcNanoViricides (NYSEMKT:NNVC) jumps 36% after hours in reaction to its announcement related to its development plans for a drug to treat COVID-19 infection. Management intends to conduct initial testing of its drug candidates in its own virology laboratory using low-threat coronavirus strains that have been normally circulating in the human population. If successful, it has the ability to make "kilogram quantities" in just a few weeks which, it says, would be sufficient to treat several hundred to a few thousand patients. Source seeking alpha
AMEX:NNVCLong
by RedHotStocks
2
NanoViricides, Inc confirms Flu Virus Program SHELTON, CT / ACCESSWIRE / January 30, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus. "We have already initiated a program for developing a treatment for the 2019-nCOV," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases. Of course, we will need support from governmental and international agencies such as the US CDC, WHO, and Chinese CDC to successfully develop these treatments, and, if developed, to get them to the patients in the fastest possible time. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. We had collaborations with the CDC and USAMRIID in the past. The Company intends to pursue a relevant collaboration for testing of our drug candidates soon." The new 2019-nCoV is known to be closely related to the SARS-CoV of 2002-2003 epidemic. In fact it has been shown to use the same cell surface receptor as SARS-CoV, namely ACE2. "We have already found some lead candidate ligands in our chemical library that can bind to the SARS-CoV spike protein in the same fashion as it binds to the cognate receptor, ACE2, using molecular modeling tools," explained Dr. Diwan, adding, "We believe this means we may already be significantly ahead in developing a potential treatment for the new Wuhan virus."
AMEX:NNVC
by DEXWireNews